MAPT and Alzheimer disease: α4β1 integrin targeting in 3xTg-AD mice using an anti-α4β1 antibody resulted in a significant decrease in AD severity by reducing disease-associated pathological processes, i.e. microgliosis or tau hyperphosphorylation and improvement of cognitive functions in animals [113].